Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
January 29, 2014 18:31 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the...
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
November 24, 2013 19:16 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
November 22, 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal...
Mesoblast's Mesenchymal Precursor Cells Induce Functional Recovery in Ischemic Stroke Model
November 11, 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced positive preclinical trial results which...
MESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
October 28, 2013 01:11 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in...
Mesoblast, Intrexon and ZIOPHARM to Target Cancers
October 23, 2013 18:28 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE: XON),...
Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
June 25, 2013 21:12 ET
|
Mesoblast
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Key Points:∙ Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or “off-the-shelf”,...
Key Mesenchymal Precursor Cell Patent Granted in Japan
June 04, 2013 20:47 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the...
MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR
April 22, 2013 04:07 ET
|
Mesoblast
Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...
Mesoblast Completes A$170m Private Placement
March 13, 2013 23:08 ET
|
Mesoblast
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its...